Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Progression from non-radiographic to radiographic AxSpA is not the norm
● 16% progress over 5 years, 10-25% over 10 years
● Syndesmophytes in 20% over 4 years
● Male, MRI+ at baseline, response to NSAIDs are predictors of progression
Jose U Scher, Review @RheumNow #ACR22 https://t.co/FatodINTfn
Dr. Antoni Chan synovialjoints
3 years 1 month ago
ASAS-EULAR Rec for AxSpA 2022
◦ NSAIDs are first line
◦ b/tsDMARDs when ASDAS >2.1
◦ Uveitis/IBD ➤TNFi
◦ Psoriasis ➤IL-17i
◦ Review Dx if Rx failure
◦ Switch if active disease confirmed
◦ Taper bDMARDs if sustained remission
Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/8fGwlZWBDS
Dr. Antoni Chan synovialjoints
3 years 1 month ago
IL-17i Ixekizumab (IXE) continuation superior to withdrawal in preventing relapse in PsA
● Withdrawal resulted in relapse at median 22 wk
● Continuation vs withdrawal 38% vs 85% relapse
● 96% regained control after reinstating IXE
Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/TgIRe14Vud
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Think of paraneoplastic presentations for
◦ RS3PE 16-30% malignancy
◦ PPP 12% pancreatic ca
◦ HPOA 1% lung ca
◦ EF 10% haem ca
◦ LCV 4% malignancy
◦ Erythromelalgia 10% haem ca
Screen for malignancies esp if treatment resistant
Capelli L #ReviewCourse @RheumNow #ACR22 https://t.co/tEaf7wCAcj
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Not all dry eyes and mouth is due to Sjogren’s syndrome (SS). Think of mimics including diabetes, HCV, HIV, sarcoidosis.
Equally, not all parotid enlargement is due to SS. Think of mimics including IgG4, sialodenosis #ReviewCourse @RheumNow #ACR22 https://t.co/zPwRRtdGjT
Dr. Rachel Tate uptoTate
3 years 1 month ago
The calm before the #ACR22 deluge! Let’s go learn! Follow https://t.co/nDsfMGdiq8 for our conference coverage! @RheumNow #rheumpix @doctorRBC @DrPetryna @KDAO2011 @RichardPAConway @ericdeinmd @EBRheum @gensler_MD @Janetbirdope and more! https://t.co/nTX48dWA4g
Dr. John Cush RheumNow
3 years 1 month ago
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR22 meeting in Philadelphia.
https://t.co/WGUYSUmFYz https://t.co/yGSROf5XU6
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Methotrexate (MTX) works in early PsA. Confirms what we see in clinical practice
◦ Mean disease duration 0.6y
◦ bDMARD naive
◦ MTX monotherapy
➢ ACR20 50.7%
➢ ACR50 30.6%
➢ MDA 22.9%
Good to know, our trusted friend MTX works
Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/ECyM4qtliG
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Treatment algorithm for Raynaud’s secondary to systemic sclerosis
CCB ➤ PDE5i ➤ ARB ➤ Prostanoid ➤ Switch CCB
John Pauling #ReviewCourse @RheumNow #ACR22 https://t.co/UXFpKdRuC5
Dr. John Cush RheumNow
3 years 1 month ago
Low dose IL-2 works in Primary Sjogrens Syndr (pSS)? RCT 60 pSS pts rx w/ PBO vs LD-IL-2; latter lower ESSDAI @wk 24 (67% vs 27%; P=.004) & less Sxs (dryness,fatigue) @wk12 and expansion of TREGs & CD24highCD27+ B cells. https://t.co/39U6WX7ceM https://t.co/i56XDSvGXs
The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters.
Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions (Oral Presentation, Abstract 2247, Monday, November 14, 2022, 4:30-6:00pm ET)
Dr. John Cush RheumNow
3 years 1 month ago
Dr. Olga Petryna is back for her 8th year as a RheumNow reporter. Follow her @DrPetryna for real-time #ACR22 coverage. https://t.co/zwCt46uqQj
Dr. John Cush RheumNow
3 years 1 month ago
Introducing RheumNow #ACR22 reporter, Dr. Catherine Sims! She'll will be joining us and reporting on SpA and reproductive health. Follow @DrCassySims for real-time ACR coverage this weekend! https://t.co/LU39uYs6WM
Dr. John Cush RheumNow
3 years 1 month ago
Hear what KOLs are saying about #ACR22. We are featuring Drs: Michele Petri, Peter Nash, Artie Kavanaugh, Jack Cush. Follow us on Twitter and head to https://t.co/V10S4oE43V for real-time coverage. https://t.co/Qj8tSwsEiJ
TheDaoIndex KDAO2011
3 years 1 month ago
Which one to use for prevention and which for treatment? Drugs covered by #Medicare based on indication #osteoporosis #acr22 #acrreview @RheumNow https://t.co/KE5F6Sn3wg
Poster Hall